1. Home
  2. MAIA

as of 12-08-2025 3:42pm EST

$1.24
+$0.04
+2.92%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Chart Type:
Time Range:
Founded: 2018 Country:
United States
United States
Employees: N/A City: CHICAGO
Market Cap: 44.9M IPO Year: 2022
Target Price: N/A AVG Volume (30 days): 449.7K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.77 EPS Growth: N/A
52 Week Low/High: $0.87 - $2.74 Next Earning Date: 11-07-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered MAIA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 66.44%
66.44%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of MAIA Biotechnology Inc. (MAIA)

Buy
MAIA Nov 28, 2025

Avg Cost/Share

$1.11

Shares

18,145

Total Value

$20,229.86

Owned After

437,628

SEC Form 4

Vitoc Vlad

Chief Executive Officer

Buy
MAIA Nov 28, 2025

Avg Cost/Share

$1.14

Shares

50,000

Total Value

$56,830.00

Owned After

881,421

SEC Form 4

Buy
MAIA Nov 26, 2025

Avg Cost/Share

$1.08

Shares

20,000

Total Value

$21,616.00

Owned After

437,628

SEC Form 4

Smith Stan

Director

Buy
MAIA Nov 26, 2025

Avg Cost/Share

$1.04

Shares

15,000

Total Value

$15,582.00

Owned After

1,364,289

SEC Form 4

Vitoc Vlad

Chief Executive Officer

Buy
MAIA Nov 26, 2025

Avg Cost/Share

$1.05

Shares

22,000

Total Value

$23,018.60

Owned After

881,421

SEC Form 4

Buy
MAIA Nov 25, 2025

Avg Cost/Share

$0.98

Shares

10,000

Total Value

$9,785.00

Owned After

437,628

SEC Form 4

Smith Stan

Director

Buy
MAIA Nov 25, 2025

Avg Cost/Share

$0.98

Shares

15,000

Total Value

$14,700.00

Owned After

1,364,289

SEC Form 4

Vitoc Vlad

Chief Executive Officer

Buy
MAIA Nov 25, 2025

Avg Cost/Share

$0.97

Shares

10,500

Total Value

$10,144.05

Owned After

881,421

SEC Form 4

Smith Stan

Director

Buy
MAIA Nov 24, 2025

Avg Cost/Share

$0.99

Shares

10,000

Total Value

$9,900.00

Owned After

1,364,289

SEC Form 4

Vitoc Vlad

Chief Executive Officer

Buy
MAIA Nov 24, 2025

Avg Cost/Share

$0.99

Shares

10,000

Total Value

$9,891.00

Owned After

881,421

SEC Form 4

Latest MAIA Biotechnology Inc. News

MAIA Breaking Stock News: Dive into MAIA Ticker-Specific Updates for Smart Investing

All MAIA News

Share on Social Networks: